Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "sandoz inc"

Amgen Urges Court to Block Novartis Neupogen Biosimilar Launch
Pharmaceutical Manufacturing Magazine

Amgen, Inc. Files Petition To Stop Novartis (NVS) From Launchi...

Amgen Inc ( NYSE: AMGN ) is seeking a preliminary injunction against Sandoz, a subsidiary of Novartis AG ADR ( NYSE: NVS ) over its application for the biosimilar copy of Amgen's blockbuster drug, Neupogen, for the treatment of neutropenia in caner ... Bidness Etc, 2 weeks ago
Amgen Urges Court to Block Novartis Neupogen Biosimilar Launch Pharmaceutical Manufacturing Magazine, 2 weeks ago
NOVARTIS : Making the case for biosimilars 4 Traders, 3 weeks ago

1 images for "sandoz inc"

Livemint.com, 1 month ago

Spectrum Pharms., Inc. v. Sandoz Inc.,

Winter 2014 Case Name: Spectrum Pharms., Inc. v. Sandoz Inc. , No. 2:12-cv-111-GMN-NJK, 2014 U.S. Dist. LEXIS 179755 (D. Nev. Dec. 29, 2014) (Navarro, J.) (Because the ANDA product did not meet the claimed dosage strength, summary-judgment of ...
 JD Supra1 week ago Will Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. Change Patent Litigation?  JD Supra1 week ago Sandoz Inc. v. Amgen Inc.,  JD Supra1 week ago No Declaratory Jurisdiction Without Biosimilarity Application on File with FDA - Sandoz Inc. v. Amgen Inc.  JD Supra2 weeks ago
[x]  

Anacor Pharmaceuticals to Present at the 35th Annual Cowen Health Care Conference

PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company's Chairman, President and Chief Executive Officer, will provide a company overview at the 35 th Annual Cowen Health Care ...
 CNBC3 days ago ANACOR PHARMACEUTICALS : to Present at the 35th Annual Cowen Health Care Conference  4 Traders3 days ago
[x]  
Seeking Alpha

Why Spectrum Pharmaceuticals, Inc.'s Shares Collapsed

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Spectrum Pharmaceuticals (NASDAQ: SPPI So what: ...
 Motley Fool5 days ago Morning Buzz: Rigel Pharmaceuticals (RIGL), Celldex (CLDX), Tower Semiconductor (TSEM), Digital Ally (DGLY), Spectrum (SPPI)  Wall Street Pit5 days ago Spectrum Pharmaceuticals (SPPI) plummets on lawsuit, downgrade  BayStreet.ca5 days ago Spectrum Pharmaceuticals: Update Following District Court Invalidation Of Certain Claims Of The '829 Patent  Seeking Alpha6 days ago
[x]  

Momenta (MNTA) Posts Wider-than-Expected Loss in Q4 - Analyst Blog

Momenta Pharmaceuticals Inc. (MNTA) reported fourth-quarter 2014 loss of 31 cents per share, wider than the Zacks Consensus Estimate of a loss of 16 cents. However, fourth-quarter loss was narrower than the year-ago loss of 59 cents per share. ...
 Yahoo! Finance1 week ago Momenta Pharmaceuticals Inc. (MNTA): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report  Zacks.com3 weeks ago
Nasdaq

Pssst... Pfizer Just Told Investors That This is the Next Big Thing

Source: Flickr user Bill Brooks . When drugmaking Goliath Pfizer recently agreed to purchase Hospira Inc . , a maker of specialty drugs and biosimilas, it sent a signal to investors that biosimilars could be the next big thing in healthcare. ...
 Nasdaq1 week ago Pfizer Inc. GEP Unit To Become Largest Biosimilar And Generic Drugs Developer  Bidness Etc2 weeks ago

Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results

CAMBRIDGE, Mass., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. ( Nasdaq:MNTA ) today reported its financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, the company reported a ...
 Franklin Credit Management Corporation1 week ago Momenta Pharmaceuticals, Inc. Reports Fourth Quarter and Year End 2014 Financial Results  BioSpace1 week ago Momenta Pharmaceuticals Is A Low-Risk, High-Reward Long-Term Gamble  Seeking Alpha3 weeks ago
[x]  
Nasdaq

Antares Pharma: Preparing For An Inflection Point

Feb. 6, 2015 9:32 AM ET | About: Antares Pharma Inc. (ATRS), Includes: TEVA by: Subscribers to SA PRO had an early look at this article. Learn more about PRO ยป Summary Antares makes changes to Otrexup sales strategy. A deep look into ...
 Seeking Alpha3 weeks ago Teva Pharmaceutical's Strategy Proves to be Brilliant  Nasdaq3 weeks ago

Apricus Biosciences Announces $11 Million Registered Direct Offering With Sarissa Capital Management

SAN DIEGO, Feb. 11, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI ), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has entered into definitive agreements with ...
 FirstWord Pharma2 weeks ago Apricus Biosciences expands license agreement with Hexal  Individual.com3 weeks ago Apricus Biosciences Expands Exclusive License Agreement With an Existing Partner to Market Vitaros(R) in Select Asia-Pacific Countries  A.M. Best3 weeks ago Apricus Biosciences to Present at the 17th Annual BIO CEO & Investor Conference  Review Seeker3 weeks ago
[x]  

An Update On Epirus In Light Of Recent Developments

Feb. 4, 2015 9:47 AM ET | About: EPIRUS Biopharmaceuticals, Inc (EPRS), Includes: HSP by: Brendan O'Boyle Summary Recent developments regarding the approval of U.S. biosimilars are discussed. Epirus has also made a secondary offering this ...
 Seeking Alpha3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less